JPH0363529B2 - - Google Patents
Info
- Publication number
- JPH0363529B2 JPH0363529B2 JP57034314A JP3431482A JPH0363529B2 JP H0363529 B2 JPH0363529 B2 JP H0363529B2 JP 57034314 A JP57034314 A JP 57034314A JP 3431482 A JP3431482 A JP 3431482A JP H0363529 B2 JPH0363529 B2 JP H0363529B2
- Authority
- JP
- Japan
- Prior art keywords
- monomers
- pressure
- polyfunctional
- sensitive adhesive
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 37
- 229940079593 drug Drugs 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 31
- 239000000178 monomer Substances 0.000 claims description 28
- 229920001577 copolymer Polymers 0.000 claims description 25
- -1 acrylic ester Chemical class 0.000 claims description 19
- 239000002390 adhesive tape Substances 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 18
- 239000010410 layer Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 10
- 238000006116 polymerization reaction Methods 0.000 claims description 7
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 6
- 229920002554 vinyl polymer Polymers 0.000 claims description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
- JHPBZFOKBAGZBL-UHFFFAOYSA-N (3-hydroxy-2,2,4-trimethylpentyl) 2-methylprop-2-enoate Chemical compound CC(C)C(O)C(C)(C)COC(=O)C(C)=C JHPBZFOKBAGZBL-UHFFFAOYSA-N 0.000 claims description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 description 11
- 230000001070 adhesive effect Effects 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000007334 copolymerization reaction Methods 0.000 description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 7
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 6
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 description 4
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 3
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 239000004641 Diallyl-phthalate Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- QUDWYFHPNIMBFC-UHFFFAOYSA-N bis(prop-2-enyl) benzene-1,2-dicarboxylate Chemical compound C=CCOC(=O)C1=CC=CC=C1C(=O)OCC=C QUDWYFHPNIMBFC-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000003851 corona treatment Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000005442 diisocyanate group Chemical group 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 2
- 125000005395 methacrylic acid group Chemical group 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- KOMNUTZXSVSERR-UHFFFAOYSA-N 1,3,5-tris(prop-2-enyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C=CCN1C(=O)N(CC=C)C(=O)N(CC=C)C1=O KOMNUTZXSVSERR-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- CFVWNXQPGQOHRJ-UHFFFAOYSA-N 2-methylpropyl prop-2-enoate Chemical compound CC(C)COC(=O)C=C CFVWNXQPGQOHRJ-UHFFFAOYSA-N 0.000 description 1
- ZVYGIPWYVVJFRW-UHFFFAOYSA-N 3-methylbutyl prop-2-enoate Chemical compound CC(C)CCOC(=O)C=C ZVYGIPWYVVJFRW-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- XYLMUPLGERFSHI-UHFFFAOYSA-N alpha-Methylstyrene Chemical compound CC(=C)C1=CC=CC=C1 XYLMUPLGERFSHI-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- ZPOLOEWJWXZUSP-WAYWQWQTSA-N bis(prop-2-enyl) (z)-but-2-enedioate Chemical compound C=CCOC(=O)\C=C/C(=O)OCC=C ZPOLOEWJWXZUSP-WAYWQWQTSA-N 0.000 description 1
- SYFOAKAXGNMQAX-UHFFFAOYSA-N bis(prop-2-enyl) carbonate;2-(2-hydroxyethoxy)ethanol Chemical compound OCCOCCO.C=CCOC(=O)OCC=C SYFOAKAXGNMQAX-UHFFFAOYSA-N 0.000 description 1
- FPODCVUTIPDRTE-UHFFFAOYSA-N bis(prop-2-enyl) hexanedioate Chemical compound C=CCOC(=O)CCCCC(=O)OCC=C FPODCVUTIPDRTE-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- JBSLOWBPDRZSMB-FPLPWBNLSA-N dibutyl (z)-but-2-enedioate Chemical compound CCCCOC(=O)\C=C/C(=O)OCCCC JBSLOWBPDRZSMB-FPLPWBNLSA-N 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Chemical group OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- PBOSTUDLECTMNL-UHFFFAOYSA-N lauryl acrylate Chemical compound CCCCCCCCCCCCOC(=O)C=C PBOSTUDLECTMNL-UHFFFAOYSA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 150000007974 melamines Chemical class 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- NZIDBRBFGPQCRY-UHFFFAOYSA-N octyl 2-methylprop-2-enoate Chemical compound CCCCCCCCOC(=O)C(C)=C NZIDBRBFGPQCRY-UHFFFAOYSA-N 0.000 description 1
- ANISOHQJBAQUQP-UHFFFAOYSA-N octyl prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=C ANISOHQJBAQUQP-UHFFFAOYSA-N 0.000 description 1
- DBSDMAPJGHBWAL-UHFFFAOYSA-N penta-1,4-dien-3-ylbenzene Chemical compound C=CC(C=C)C1=CC=CC=C1 DBSDMAPJGHBWAL-UHFFFAOYSA-N 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 239000002685 polymerization catalyst Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- HJWLCRVIBGQPNF-UHFFFAOYSA-N prop-2-enylbenzene Chemical compound C=CCC1=CC=CC=C1 HJWLCRVIBGQPNF-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010557 suspension polymerization reaction Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Description
【発明の詳細な説明】
本発明は治療用接着テープもしくはシートに関
する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to therapeutic adhesive tapes or sheets.
基材に、治療用薬剤を混入させた感圧性接着剤
層が薄層状に設けられた治療用接着テープもしく
はシートを被着体である皮膚に貼付け、感圧性接
着剤層から滲出する薬剤により局所治療を行なう
ことが、従来の密封包帯療法（ODT療法）に代
る新た治療方法として注目されている。 A therapeutic adhesive tape or sheet with a thin layer of pressure-sensitive adhesive mixed with a therapeutic drug is applied to the skin as a base material, and the drug that exudes from the pressure-sensitive adhesive layer acts locally. This treatment is attracting attention as a new treatment method to replace the conventional occlusive dressing therapy (ODT therapy).
このよう治療用接着テープもしくはシートに要
求される性能は、感圧性接着剤が皮膚に対し強い
刺激を与えないこと、皮膚に貼付しやすく剥すに
際して接着剤の皮膚への付着や過度な接着力によ
り苦痛を与えないこと、感圧性接着剤と薬剤との
間の相互化学作用がないこと、薬効が充分得られ
るように薬剤が接着剤中から経済的に表面に滲出
しやすいこと等である。 The performance required for therapeutic adhesive tapes or sheets is that the pressure-sensitive adhesive does not cause strong irritation to the skin, and that it is easy to apply to the skin and that when removed, there is no risk of the adhesive sticking to the skin or excessive adhesive force. The adhesive should not cause pain, there should be no mutual chemical interaction between the pressure-sensitive adhesive and the drug, and the drug should be easily leached from the adhesive to the surface in an economical manner so that a sufficient medicinal effect can be obtained.
従来はこの目的に供する感圧性接着剤として、
アクリル酸エステルを主成分とし、これにアクリ
ル酸、メタクリル酸、グリコールモノアクリレー
ト、グリコールメタクリレート、グリシジルメタ
クリレート等の化学活性基を有する単量体が共重
合され、更にジアミン類、ジイソシアネート類、
ジカルボン酸類、グリコール類、アルキル化メラ
ミン類、有機多価金属化合物等により化学架橋を
生じさせ、アクリル酸エステルだけでは不足する
接着力と内部凝集力を補つている。 Conventionally, pressure-sensitive adhesives used for this purpose,
The main component is acrylic ester, which is copolymerized with monomers having chemically active groups such as acrylic acid, methacrylic acid, glycol monoacrylate, glycol methacrylate, and glycidyl methacrylate, and further diamines, diisocyanates,
Chemical crosslinks are created using dicarboxylic acids, glycols, alkylated melamines, organic polyvalent metal compounds, etc. to compensate for the insufficient adhesive strength and internal cohesive force of acrylic esters alone.
しかしながら上記感圧性接着剤層を設けた治療
用接着テープもしくはシートにおいては、薬剤が
感圧性接着剤中の化学活性基と反応して薬効を損
なうこと、薬剤が化学活性基と反応しない場合で
も化学的親和力によつて薬剤と感圧性接着剤との
相溶性が過度に向上し薬剤が滲出し難くなるこ
と、感圧性接着剤中の化学活性基は人体等の被着
体に対しても化学的親和力を有するので、貼付後
時間の経過に従つて接着力が向上し剥す際に痛
み、苦痛を感ずる等の欠点があつた。 However, in therapeutic adhesive tapes or sheets provided with the pressure-sensitive adhesive layer, the drug may react with the chemically active groups in the pressure-sensitive adhesive, impairing its efficacy, and even if the drug does not react with the chemically active groups, the chemical The compatibility between the drug and the pressure-sensitive adhesive increases excessively due to chemical affinity, making it difficult for the drug to ooze out, and the chemically active groups in the pressure-sensitive adhesive are chemically sensitive to adherends such as the human body. Since it has affinity, the adhesion strength improves as time passes after application, resulting in pain and discomfort when peeled off.
本発明は上記の欠点を解消し、感圧性接着剤層
に含まれる薬剤が効果的に皮膚に移行すると共
に、その移行性が経時的に変化せず、常に安定し
た治療効果が得られる治療用接着テープもしくは
シートを提供することを目的とする。 The present invention solves the above-mentioned drawbacks, and provides a therapeutic device that allows the drug contained in the pressure-sensitive adhesive layer to effectively transfer to the skin, and that the transferability does not change over time, providing a stable therapeutic effect at all times. The purpose is to provide adhesive tapes or sheets.
本発明の要旨は、基材に、薬剤を含有する感圧
性接着剤層が設けられてなる治療用接着テープも
しくはシートにおいて、感圧性接着剤が、(A)アク
リル酸エステル又は（及び）メタクリル酸エステ
ルと、(B)多官能性ビニル単量体、多官能性アリル
単量体、多官能性アミド単量体から選択される一
種以上の多官能性単量体0.01〜１モル％とを共重
合させて得られる共重合体よりなることを特徴と
する、治療用接着テープもしくはシートに存す
る。 The gist of the present invention is to provide a therapeutic adhesive tape or sheet in which a base material is provided with a pressure-sensitive adhesive layer containing a drug, in which the pressure-sensitive adhesive is (A) an acrylic ester or (and) a methacrylic acid ester. Ester and (B) 0.01 to 1 mol% of one or more polyfunctional monomers selected from polyfunctional vinyl monomers, polyfunctional allyl monomers, and polyfunctional amide monomers. The present invention relates to a therapeutic adhesive tape or sheet comprising a copolymer obtained by polymerization.
次に本発明治療用接着テープもしくはシートに
ついて更に詳細に説明する。 Next, the therapeutic adhesive tape or sheet of the present invention will be explained in more detail.
本発明に用いられる基材としては、ポリエチレ
ン、ポリプロピレン、エチレン−酢酸ビニル共重
合体、軟質ポリ塩化ビビニル、セロハン等の可撓
性を有する材質からなるものが好適に使用され
る。基材の厚みとしては0.02乃至0.15mmの範囲が
好ましい。 The base material used in the present invention is preferably made of a flexible material such as polyethylene, polypropylene, ethylene-vinyl acetate copolymer, soft polyvinyl chloride, or cellophane. The thickness of the base material is preferably in the range of 0.02 to 0.15 mm.
前記基材には必要に応じ感圧性接着剤層との密
着力を高めるために、コロナ放電処理、プラズマ
処理、下塗剤塗工等が施される。 The base material is subjected to corona discharge treatment, plasma treatment, primer coating, etc., if necessary, in order to increase the adhesion with the pressure-sensitive adhesive layer.
感圧性接着剤はメタクリル酸エステル又は（及
び）アクリル酸エステル（共重合成分(A)）と、多
官能性ビニル単量体は、多官能性アリル単量体、
多官能性アミド単量体から選択される一種以上の
多官能性単量体（共重合成分(B)）0.01〜１モル％
とを共重合させて得られる共重合体よりなる。 The pressure-sensitive adhesive is a methacrylic ester or (and) an acrylic ester (copolymerization component (A)), the polyfunctional vinyl monomer is a polyfunctional allyl monomer,
0.01 to 1 mol% of one or more polyfunctional monomers selected from polyfunctional amide monomers (copolymerization component (B))
It consists of a copolymer obtained by copolymerizing these.
感圧性接着剤が共重合成分(A)としてアクリル酸
エステル又は（及び）メタクリル酸エステルを含
有するのは、これらが化学的活性基を有しないた
め薬剤との相互化学作用を生じないので薬効を損
なうことがなく、薬剤の滲出性が良好となり、又
皮膚に対する強い刺激を与えることがないからで
ある。 The reason why pressure-sensitive adhesives contain acrylic esters or (and) methacrylic esters as the copolymer component (A) is that they do not have chemically active groups and do not interact with drugs, so they have no medicinal effect. This is because the drug does not damage the skin, has good exudation properties, and does not cause strong irritation to the skin.
前記共重合体の共重合成分となるアクリル酸エ
ステル又は（及び）メタクリル酸エステルにおけ
るエステル残基としては、例えばメチル基、エチ
ル基、プロピル基、イソプロピル基、ｎ−ブチル
基、イソブチル基、ｎ−ペンチル基、イペンチル
基、２−メチルブチル基、ｎ−ヘキシル基、２−
メチルペンチル基、３−メチルペンチル基、２−
エチルブチル基、ｎ−オクチル基、イソオクチル
基、２−エチルヘキシル基、ノニル基、ｎ−デシ
ル基、ラウリル基等である。そして特に好適なア
クリル酸エステルとしては、エチルアクリレー
ト、ｎ−ブチルアクリレート、イソブチルアクリ
レート、イソアミルアクリレート、２−エチルヘ
キシルアクリレート、ｎ−オクチルアクリレー
ト、ラウリルアクリレート等であり、またメタク
リル酸エステルとしては、メチルメタアクリレー
ト、ブチルメタクリレート、２−エチルヘキシル
メタクリレート、ｎ−オクチルメタクリレート、
ラウリルメタクリレート等である。 Examples of ester residues in the acrylic ester or (and) methacrylic ester which become the copolymerization component of the copolymer include methyl group, ethyl group, propyl group, isopropyl group, n-butyl group, isobutyl group, n- Pentyl group, ipentyl group, 2-methylbutyl group, n-hexyl group, 2-
Methylpentyl group, 3-methylpentyl group, 2-
Examples include ethylbutyl group, n-octyl group, isooctyl group, 2-ethylhexyl group, nonyl group, n-decyl group, and lauryl group. Particularly suitable acrylic esters include ethyl acrylate, n-butyl acrylate, isobutyl acrylate, isoamyl acrylate, 2-ethylhexyl acrylate, n-octyl acrylate, lauryl acrylate, etc., and methacrylic esters include methyl methacrylate. , butyl methacrylate, 2-ethylhexyl methacrylate, n-octyl methacrylate,
lauryl methacrylate, etc.
ところで感圧性接着剤がアクリル酸エステルだ
けの重合体である場合は、皮膚への感圧性接着剤
の移行や感圧性接着剤の位置ずれを防ぐために必
要な内部凝集力及び皮膚への貼着力を付与する接
着力に乏しいものとなり、メタクリル酸エステル
だけの重合体では内部凝集力は得られるが皮膚に
対する粘着力が発現しない。又アクリル酸エステ
ルとメタクリル酸エステルの共重合体では僅かに
内部凝集力が不足したものとなるので、内部凝集
力を不足した分だけ上させる必要がある。 By the way, when the pressure-sensitive adhesive is a polymer made only of acrylic ester, it is necessary to maintain the internal cohesive force and adhesion force to the skin necessary to prevent the pressure-sensitive adhesive from transferring to the skin or from shifting its position. The adhesive force provided is poor, and a polymer made only of methacrylic acid ester can provide internal cohesive force, but does not exhibit adhesive force to the skin. In addition, since the copolymer of acrylic ester and methacrylic ester has a slightly insufficient internal cohesive force, it is necessary to increase the internal cohesive force by the amount that is insufficient.
このために本発明では、感圧性接着剤は前記共
重合成分(A)と共重合成分(B)を含有する共重合体と
している。 For this reason, in the present invention, the pressure-sensitive adhesive is a copolymer containing the copolymer component (A) and the copolymer component (B).
共重合成分(B)として多官能性ビニル単量体、多
官能性アクリル単量体、多官能性アミド単量体か
ら選択される一種以上の多官能性単量体が使用さ
れる。 As the copolymerization component (B), one or more polyfunctional monomers selected from polyfunctional vinyl monomers, polyfunctional acrylic monomers, and polyfunctional amide monomers are used.
多官能性ビニル単量体は、１分子中に２個以上
のビニル基を有する化合物であり、例えばジビニ
ルベンゼン、ジビニルトルエン等が存する。多官
能性アクリル単量体は１分子中に２個以上のアリ
ル基を有する化合物であり、例えばジアリルフタ
レート、ジアリルマレエート、ジアリルアジペー
ト、ジアリルグリコレート、トリアリルイソシア
ヌレート、ジエチレングリコールビスアリルカー
ボネート、等が存する。 The polyfunctional vinyl monomer is a compound having two or more vinyl groups in one molecule, and includes, for example, divinylbenzene and divinyltoluene. Polyfunctional acrylic monomers are compounds having two or more allyl groups in one molecule, such as diallyl phthalate, diallyl maleate, diallyl adipate, diallyl glycolate, triallyl isocyanurate, diethylene glycol bisallyl carbonate, etc. exists.
又多官能性アミド単量体は、１分子中に２個以
上のアミド基を有する化合物であり、例えばメチ
レンビスアクリルアミドが存する。共重合成分(B)
は共重合体中に0.01〜１モル％の範囲で共重合に
関与される。これは共重合成分(B)が共重合体中に
0.01モル％よりも少ない場合は、得られる共重合
体は接着剤としての内部凝集力が小さく、皮膚か
ら剥された際の皮膚への付着が生じやすくなり、
又１モル％よりも多い場合は、共重合体を得るた
めに重合反応を行なわせる間にゲル化を生じやす
く、塗工が困難となつてしまうことによる。又、
１モル％よりも多い場合は、共重合成分(B)が未反
応成分として残る可能性が高くなるので好ましく
ない。 Further, the polyfunctional amide monomer is a compound having two or more amide groups in one molecule, and includes, for example, methylenebisacrylamide. Copolymerization component (B)
is involved in the copolymerization in a range of 0.01 to 1 mol%. This is because the copolymer component (B) is in the copolymer.
If it is less than 0.01 mol%, the resulting copolymer will have a small internal cohesive force as an adhesive, and will tend to stick to the skin when removed from the skin.
If the amount is more than 1 mol %, gelation tends to occur during the polymerization reaction to obtain the copolymer, making coating difficult. or,
If it is more than 1 mol %, it is not preferable because the copolymerization component (B) is likely to remain as an unreacted component.
本発明において、感圧性接着剤が、共重合成分
(A)と共重合成分(B)との共重合体の他に、これらと
共重合可能であつて化学的活性基を有しない他の
重合性単量体（共重合成分(C)）、すなわち薬剤と
の相互作用を生ずるおそれがない他の重合性単量
体を共重合成分とする場合を包含する。共重合成
分(C)が使用されるのは、例えば薬剤との相溶性を
調節することにより薬剤が結晶したり、表面に析
出したり、薬剤の滲出を抑制する働きを期待する
場合である。かゝる共重合成分(C)としては、例え
ば酢酸ビニル、塩化ビニルル、スチレン、α−メ
チルスチレン、ビニルトルエン、アクリロニトリ
ル、ジブチルマレエート、ブタジエン、イソプレ
ン等が存する。 In the present invention, the pressure sensitive adhesive is a copolymer component.
In addition to the copolymer of (A) and copolymer component (B), other polymerizable monomers that can be copolymerized with these and do not have chemically active groups (copolymer component (C)), That is, it includes cases where other polymerizable monomers that are not likely to interact with the drug are used as copolymerization components. The copolymer component (C) is used, for example, when it is expected to have the effect of controlling crystallization of the drug, precipitation on the surface, or leaching of the drug by adjusting its compatibility with the drug. Examples of such copolymerization component (C) include vinyl acetate, vinyl chloride, styrene, α-methylstyrene, vinyltoluene, acrylonitrile, dibutyl maleate, butadiene, and isoprene.
感圧性接着剤の製造に当つては、通常のラジカ
ル重合触媒、例えばアゾビス系化合物、過酸化系
化合物を用いることにより溶液重合、エマルジヨ
ン重合、懸濁重合等ご行なえばよいが、後工程と
なる薬剤の混合、溶解工程を考えると溶液重合が
最適である。 In the production of pressure-sensitive adhesives, solution polymerization, emulsion polymerization, suspension polymerization, etc. can be carried out using ordinary radical polymerization catalysts such as azobis compounds and peroxide compounds, but this is a post-process. Considering the mixing and dissolving process of the drug, solution polymerization is optimal.
例えば反応容器内に、共重合体を構成する各成
分及び酢酸エチル等の溶媒を加えて約60重量％濃
度の溶液となし、反応容器内の雰囲気を窒素ガス
で置換し、撹拌しながら昇温し、60乃至80℃の温
度において、ラジカル発生触媒を同じ溶媒によつ
て溶解した溶液を滴下するが分割注入し、粘度の
上昇に応じて溶媒のみを追加しながら粘度を抑制
し、全体として10乃至20時間で重合を完了する。
このようにして感圧性接着剤の溶液が作製された
後、薬剤がそのまゝあるいは適当な溶媒に溶解し
て加えられる。薬剤としては、ヒドロコルチゾ
ン、酢酸ヒドロコルチゾン、プレドニゾロン、デ
キサメタゾン、ペタメタゾン、フルオシノアセト
ニド等の副腎質ホルモン；サリチル酸メチル、サ
リチル酸モノグリコール等の消炎鎮痛剤；抗ヒス
タミン剤；抗真菌剤等が目的に応じて適宜使用さ
れる。感圧性接着剤中に含有される薬剤の量とし
ては、感圧性接着剤層のみ、薬剤の種類等により
異なるが、感圧性接着剤層１cm2当り1μｇ〜５mg
の範囲が好ましい。 For example, add each component constituting the copolymer and a solvent such as ethyl acetate into a reaction vessel to make a solution with a concentration of approximately 60% by weight, replace the atmosphere inside the reaction vessel with nitrogen gas, and raise the temperature while stirring. Then, at a temperature of 60 to 80°C, a solution of the radical generating catalyst dissolved in the same solvent is added dropwise, but the viscosity is controlled by adding only the solvent according to the increase in viscosity, and the viscosity is suppressed to 10% as a whole. Polymerization is completed in 20 hours.
After the pressure-sensitive adhesive solution is prepared in this manner, the drug is added as such or dissolved in a suitable solvent. Medications include adrenal hormones such as hydrocortisone, hydrocortisone acetate, prednisolone, dexamethasone, petamethasone, and fluocinoacetonide; anti-inflammatory analgesics such as methyl salicylate and monoglycol salicylate; antihistamines; antifungal agents, etc. are used as appropriate depending on the purpose. be done. The amount of the drug contained in the pressure-sensitive adhesive layer varies depending on the type of drug, etc., but it is 1 μg to 5 mg per 1 cm 2 of the pressure-sensitive adhesive layer.
A range of is preferred.
感圧性接着剤は基材に塗布、乾燥され、例えば
0.02乃至0.2mmのみに形成され、次いで剥離性シ
ートをロール等を通して圧着するか、又は、先に
剥離性シートの面上に感圧性接着剤の溶液を塗
布、乾燥し、ロールを通して基材を粘着面上に圧
着することにより、感圧性接着剤層が保護された
治療用接着テープもしくはシートが得られる。 Pressure-sensitive adhesives are applied to a substrate and dried, e.g.
Formed to a thickness of only 0.02 to 0.2 mm, the releasable sheet is then pressed through a roll or the like, or a pressure-sensitive adhesive solution is first applied on the surface of the releasable sheet, dried, and the base material is adhered through a roll. By pressing onto a surface, a therapeutic adhesive tape or sheet with a protected pressure-sensitive adhesive layer is obtained.
本発明治療用接着テープもしくはシートによれ
ば、感圧性接着剤層からの薬剤の滲出性がすぐれ
るのみならず感圧性接着剤を構成する共重合体に
後架橋等を施す必要がないので、薬剤の変質を生
じ難いものであり、又残存する化学的活性基が存
在しないものとなしうるので皮膚への刺激性が著
しく小さい。更に経時的な接着力の変化を殆んど
来たすことがないものが得られ、皮膚等への接着
剤の移行現象をきたすことがないものとなる。 According to the therapeutic adhesive tape or sheet of the present invention, not only the exudation of the drug from the pressure-sensitive adhesive layer is excellent, but also there is no need to perform post-crosslinking etc. on the copolymer constituting the pressure-sensitive adhesive. It does not easily cause drug deterioration, and since there are no residual chemically active groups, irritation to the skin is extremely low. Furthermore, it is possible to obtain a product in which the adhesive strength hardly changes over time, and the adhesive does not transfer to the skin or the like.
実施例 １
２−エチルヘキシルメタクリレート2.0モル、
ブチルアクリレート3.0モル、ジビニルベンゼン
５×10-3モルの各成分を反応容器に入れ、触媒と
してアゾビスイソブチロニトリル３×10-2モル、
溶剤として酢酸エチルを加え、70℃で溶液重合
し、固形分や20重量％の共重合体溶液を得た。次
いで前記共重合体溶液100重量部当り、プレドニ
ゾロンの20重量％メタノール溶液0.6重量部を加
え、コロナ放電処理を施した厚さ0.05mmのポリエ
チレンシート上に感圧性接着剤層の厚さが0.05mm
となるように塗布、乾燥した。Example 1 2.0 mol of 2-ethylhexyl methacrylate,
3.0 mol of butyl acrylate and 5 x 10 -3 mol of divinylbenzene were placed in a reaction vessel, and 3 x 10 -2 mol of azobisisobutyronitrile was added as a catalyst.
Ethyl acetate was added as a solvent and solution polymerization was carried out at 70°C to obtain a solid content and a 20% by weight copolymer solution. Next, 0.6 parts by weight of a 20% by weight methanol solution of prednisolone was added per 100 parts by weight of the copolymer solution, and a pressure-sensitive adhesive layer with a thickness of 0.05 mm was placed on a 0.05 mm thick polyethylene sheet that had been subjected to corona discharge treatment.
It was applied and dried.
かくして得られた治療用接着テープから、試験
片を打抜き、製造直後のものと、60℃で10日間放
置したものについて、夫々イオン交換水に24時間
浸漬し、抽出された薬剤量を測定したところ、抽
出量は製造直後のものが99％であるのに対し、60
℃で10日間放置したものは98％であり、殆んど変
化しないことが認められた。又この治療用接着テ
ープを24時間皮膚に貼付したところ、端部からの
剥れはなく、剥離時の皮膚への感圧性接着剤の移
行、皮膚炎症を等を生じなかつた。 Test pieces were punched out from the thus obtained therapeutic adhesive tape, and the samples immediately after manufacture and those that had been left at 60°C for 10 days were immersed in ion-exchanged water for 24 hours, and the amount of extracted drug was measured. , the extraction amount is 60% compared to 99% immediately after production.
When left at ℃ for 10 days, the rate was 98%, and it was observed that there was almost no change. When this therapeutic adhesive tape was applied to the skin for 24 hours, there was no peeling from the edges, no transfer of the pressure sensitive adhesive to the skin upon peeling, no skin irritation, etc.
実施例 ２
実施例１において、ジビニルベンゼン５×10-3
モルにかえて、ジアリルフタレート５×10-3モル
を用いる以外は実施例１と同様にして重合反応を
行ない、薬剤を含有させた後、基材への塗布、乾
燥を行ない治療用接着テープを得た。次いで実施
例１と同様にして評価を行なつたが、薬剤の抽出
量は殆んど変化しないことが認められた。又皮膚
に貼付けた場合の端部からの剥れはなく、剥離時
の皮膚への感圧性接着剤の移行、皮膚炎症等を生
じなかつた。Example 2 In Example 1, divinylbenzene 5×10 -3
A polymerization reaction was carried out in the same manner as in Example 1 except that 5 × 10 -3 mol of diallylphthalate was used instead of mol. After incorporating the drug, it was applied to a base material and dried to form a therapeutic adhesive tape. Obtained. Next, evaluation was carried out in the same manner as in Example 1, and it was found that the amount of extracted drug hardly changed. Furthermore, when it was applied to the skin, there was no peeling from the edges, and when it was peeled off, there was no transfer of the pressure-sensitive adhesive to the skin, no skin irritation, etc.
実施例 ３
２−エチルヘキシルメタクリレート0.5モル、
ブチルメタクリレート0.5モル、ブチルアクリレ
ート4.0モル、メチレンビスアクリルアミド0.006
モルの各成分を反応容器に入れ、実施例１と同様
にして重合反応を行ない、薬剤を含有させた後、
更に基材への塗布、乾燥を行ない治療用接着テー
プを得た。次いで実施例１と同様にして評価を行
なつたが、薬剤の抽出量は殆んど変化しなかつ
た。皮膚への貼付けた場合の端部からの剥れや、
剥離時の皮膚への感圧性接着剤の移行、皮膚炎症
等を生じなかつた。Example 3 0.5 mol of 2-ethylhexyl methacrylate,
Butyl methacrylate 0.5 mol, butyl acrylate 4.0 mol, methylene bisacrylamide 0.006
After putting moles of each component into a reaction container and carrying out a polymerization reaction in the same manner as in Example 1 to incorporate the drug,
Furthermore, the adhesive tape for treatment was obtained by applying it to a base material and drying it. Next, evaluation was carried out in the same manner as in Example 1, but the extracted amount of the drug hardly changed. Peeling from the edges when applied to the skin,
There was no transfer of pressure sensitive adhesive to the skin during peeling, no skin irritation, etc.
実施例 ４
２−エチルヘキシルメタクリレート3.0モル、
ブチルアクリレート2.0モル、メチレンビスアク
リルアミド0.006モルの各成分を反応容器に入れ、
実施例１と同様にして重合反応を行ない、薬剤を
含有させた後更に基材への塗布、乾燥を行ない治
療用接着テープを得た。次いで実施例１と同様に
して評価を行なつたが、薬剤の抽出量は殆んど変
化しなかつた。皮膚へ貼付けた場合の端部からの
剥れや、剥離時の皮膚への感圧性接着剤の移行、
皮膚炎症等を生じなかつた。Example 4 3.0 mol of 2-ethylhexyl methacrylate,
2.0 mol of butyl acrylate and 0.006 mol of methylene bisacrylamide were placed in a reaction vessel.
A polymerization reaction was carried out in the same manner as in Example 1, and a drug was added thereto, followed by coating on a substrate and drying to obtain a therapeutic adhesive tape. Next, evaluation was carried out in the same manner as in Example 1, but the extracted amount of the drug hardly changed. Peeling from the edges when applied to the skin, transfer of pressure-sensitive adhesive to the skin when peeled off,
No skin irritation occurred.
比較例 １
２−エチルヘキシルアクリレート3.5モル、ブ
チルアクリレート1.0モル、メタクリル酸0.5モル
を酢酸エチル中でアゾビスイソブチロニトリル３
×10-2モルを用いて70℃で溶液重合し、固形分が
34重量％の共重合体溶液を得た。この共重合体溶
液に１，４−ジオキシテトラメチレンジヘキサメ
チレンジイソシアネート0.1モルを加えて80℃で
８時間反応させ、僅かな程度に後架橋を行ない、
感圧性接着剤を得た。Comparative Example 1 3.5 mol of 2-ethylhexyl acrylate, 1.0 mol of butyl acrylate, and 0.5 mol of methacrylic acid were mixed with 3 mol of azobisisobutyronitrile in ethyl acetate.
Solution polymerization was carried out at 70℃ using ×10 -2 mol, and the solid content was
A 34% by weight copolymer solution was obtained. 0.1 mol of 1,4-dioxytetramethylene dihexamethylene diisocyanate was added to this copolymer solution and reacted at 80°C for 8 hours to perform post-crosslinking to a slight degree.
A pressure sensitive adhesive was obtained.
次いで実施例１と同様にして評価を行なつた
が、薬剤の抽出量は製造直後では72％であるのに
対し60℃で10日間放置したものは11％であり、著
しい低下が認められた。 Next, evaluation was carried out in the same manner as in Example 1, and the amount of extracted drug was 72% immediately after production, whereas it was 11% when left at 60°C for 10 days, a significant decrease was observed. .
また皮膚に貼付後、剥離時の皮膚への接着剤の
移行が生じた。 Furthermore, after it was applied to the skin, the adhesive transferred to the skin when it was peeled off.
Claims (1)
けられてなる治療用接着テープもしくはシートに
おいて、感圧性接着剤が(A)アクリル酸エステル又
は（及び）メタクリル酸エステルと、(B)多官能性
ビニル単量体、多官能性アリル単量体、多官能性
アミド単量体から選択される一種以上の多官能性
単量体0.01〜１モル％とを共重合させて得られる
共重合体よりなることを特徴とする、治療用接着
テープもしくはシート ２ 感圧性接着剤が(A)アクリル酸エステル又は
（及び）メタクリル酸エステルと、(B)多官能性ビ
ニル単量体、多官能性アリル単量体、多官能性ア
ミド単量体から選択される一種以上の多官能性単
量体0.01〜１モル％の他に、(C)これらと共重合可
能であつて化学的活性基を有しない他の重合性単
量体を共重合させて得られる共重合体よりなるこ
とを特徴とする、特許請求の範囲第１項記載の治
療用接着テープもしくはシート。[Scope of Claims] 1. A therapeutic adhesive tape or sheet in which a pressure-sensitive adhesive layer containing a drug is provided on a base material, wherein the pressure-sensitive adhesive is (A) acrylic ester or (and) methacrylic acid. Ester and (B) 0.01 to 1 mol% of one or more polyfunctional monomers selected from polyfunctional vinyl monomers, polyfunctional allyl monomers, and polyfunctional amide monomers. Therapeutic adhesive tape or sheet 2, characterized in that it consists of a copolymer obtained by polymerization.The pressure-sensitive adhesive comprises (A) an acrylic ester or (and) a methacrylic ester, and (B) a polyfunctional vinyl. In addition to 0.01 to 1 mol% of one or more polyfunctional monomers selected from monomers, polyfunctional allyl monomers, and polyfunctional amide monomers, (C) copolymerizable with these monomers; The therapeutic adhesive tape or sheet according to claim 1, characterized in that it is made of a copolymer obtained by copolymerizing another polymerizable monomer that does not have a chemically active group.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3431482A JPS58152564A (en) | 1982-03-03 | 1982-03-03 | Medical adhesive tape or sheet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3431482A JPS58152564A (en) | 1982-03-03 | 1982-03-03 | Medical adhesive tape or sheet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58152564A JPS58152564A (en) | 1983-09-10 |
| JPH0363529B2 true JPH0363529B2 (en) | 1991-10-01 |
Family
ID=12410695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3431482A Granted JPS58152564A (en) | 1982-03-03 | 1982-03-03 | Medical adhesive tape or sheet |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58152564A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2692985B2 (en) * | 1989-09-27 | 1997-12-17 | 積水化学工業株式会社 | Adhesive |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4932933A (en) * | 1972-07-26 | 1974-03-26 |
-
1982
- 1982-03-03 JP JP3431482A patent/JPS58152564A/en active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4932933A (en) * | 1972-07-26 | 1974-03-26 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58152564A (en) | 1983-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0181970B1 (en) | Percutaneously administrable pharmaceutical preparation in the form of an adhesive tape | |
| JP4663209B2 (en) | Medical contact adhesive composition containing a two-phase adhesive matrix of polyacrylate and polyamine salt | |
| JPH0363529B2 (en) | ||
| JPH0369884B2 (en) | ||
| JPH0672879A (en) | Aspirin-containing percutaneously absorbable preparation | |
| JP4380806B2 (en) | Adhesive for medical use and medical adhesive tape or sheet using the same | |
| JPH0380768B2 (en) | ||
| JPH0742228B2 (en) | Pharmaceutical formulation | |
| JPS6221395B2 (en) | ||
| JPS6320410B2 (en) | ||
| JPS59181214A (en) | Remedial adhesive tape or sheet | |
| JPS6133114A (en) | Adhesive tape or sheet for remedy | |
| JPS617369A (en) | Adhesive composition | |
| JPH0363530B2 (en) | ||
| JPH0331164B2 (en) | ||
| JP2554751B2 (en) | Patch | |
| JPS596284B2 (en) | Treatment adhesive tape or sheet | |
| JPH0372204B2 (en) | ||
| JPH064826B2 (en) | Adhesive sheet | |
| JP4097454B2 (en) | Surface-reactive functional group-modified adhesive and adhesive tape or sheet | |
| JP2554752B2 (en) | Patch | |
| JPS6221394B2 (en) | ||
| JPH0131388B2 (en) | ||
| JPH0336501Y2 (en) | ||
| JPH10298068A (en) | Medical adhesive, medical adhesive sheet by using the medical adhesive, preparation for percutaneous absorption and production of the medical adhesive |